Azitra (AZTR) Return on Capital Employed (2023 - 2026)
Azitra (AZTR) reported Return on Capital Employed of 167.94% for Q1 2026, up 3987.0% on a YoY basis from 4.11% in Q1 2025, and up 45.12% quarter-over-quarter from 305.99% in Q4 2025.
Azitra (AZTR) Return on Capital Employed (2023 - 2026) Analysis & Trends
Azitra has reported Return on Capital Employed for 4 years, with the latest figure at 167.94% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 3987.0% year-over-year to 167.94%; the trailing twelve-month figure through Mar 2026 stood at 167.94% (up 3987.0% YoY), and the FY2025 full-year result was 214.67%, up 1130.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 167.94%, up from 305.99% in the prior quarter.
- The five-year high for Return on Capital Employed was 106.55% in Q3 2023, with the low at 481.22% in Q3 2025.
- Historically, Return on Capital Employed has averaged 238.57% across 4 years, with a median of 204.28% in 2024.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 27944 bps — and 2026, when it soared 3987 bps.
- Azitra's Return on Capital Employed stood at 158.53% in 2023, then climbed by 4 bps to 152.73% in 2024, then plunged by 100 bps to 305.99% in 2025, then surged by 45 bps to 167.94% in 2026.
- The last three Return on Capital Employed figures came in at 167.94% (Q1 2026), 305.99% (Q4 2025), and 481.22% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | -167.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -167.94% |
| Dec 31, 2025 | -305.99% |
| Sep 30, 2025 | -481.22% |
| Jun 30, 2025 | -325.75% |
| Mar 31, 2025 | -207.81% |
| Dec 31, 2024 | -152.73% |
| Sep 30, 2024 | -201.78% |
| Jun 30, 2024 | -311.67% |
| Mar 31, 2024 | -204.28% |
| Dec 31, 2023 | -158.53% |
| Sep 30, 2023 | -106.55% |